Edition:
United Kingdom

Amarin Corporation PLC (AMRN.OQ)

AMRN.OQ on NASDAQ Stock Exchange Global Market

15.21USD
23 Aug 2019
Change (% chg)

$-0.35 (-2.25%)
Prev Close
$15.56
Open
$15.45
Day's High
$15.61
Day's Low
$15.17
Volume
1,092,452
Avg. Vol
1,808,429
52-wk High
$23.91
52-wk Low
$2.66

Latest Key Developments (Source: Significant Developments)

Amarin Prices Public Offering Of American Depositary Shares
Friday, 19 Jul 2019 

July 18 (Reuters) - Amarin Corporation PLC ::AMARIN PRICES PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES.AMARIN CORPORATION - ANNOUNCED PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 22,222,223 AMERICAN DEPOSITARY SHARES AT A PRICE TO PUBLIC OF $18.00 PER ADS.AMARIN CORPORATION - GROSS PROCEEDS OF OFFERING ARE EXPECTED TO BE ABOUT $400.0 MILLION.  Full Article

Amarin Announces $400 mln Public Offering Of American Depositary Shares
Wednesday, 17 Jul 2019 

July 17 (Reuters) - Amarin Corporation PLC ::AMARIN ANNOUNCES $400,000,000 PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES.AMARIN - TO USE PROCEEDS TO SUPPORT COMMERCIALIZATION OF VASCEPA ASSUMING FDA APPROVES SUPPLEMENTAL NDASEEKING EXPANDED INDICATION FOR VASCEPA IN U.S..AMARIN - MAY USE A PORTION OF NET PROCEEDS TO ACQUIRE STRATEGIC ASSETS, ALTHOUGH IT CURRENTLY HAS NO AGREEMENTS OR COMMITMENTS IN THIS REGARD..AMARIN - INTENDS TO USE NET PROCEEDS FROM OFFERING TO INCREASE COMMERCIAL SUPPLY OF VASCEPA FROM THIRD-PARTY DRUG PRODUCT SUPPLIERS.  Full Article

Amarin Provides Mid-2019 Update, Including Commercialization Plans, FY19 Revenue Guidance
Tuesday, 2 Jul 2019 

July 2 (Reuters) - Amarin Corporation PLC ::AMARIN PROVIDES MID-2019 UPDATE, INCLUDING COMMERCIALIZATION PLANS FOR VASCEPA® AND UPDATES FULL YEAR 2019 REVENUE GUIDANCE.AMARIN CORPORATION PLC - GUIDANCE FOR TOTAL 2019 REVENUE INCREASED TO A RANGE OF $380 TO $420 MILLION FROM $350 MILLION.AMARIN CORPORATION PLC - ENDED JUNE 2019 WITH NO DEBT EXCEPT REMAINING BALANCE ON ITS ROYALTY BEARING INSTRUMENT.AMARIN CORPORATION PLC - PLANS FOR COMMERCIALIZATION OF VASCEPA OUTSIDE OF UNITED STATES REMAIN UNCHANGED.AMARIN CORPORATION PLC - VASCEPA SNDA PDUFA GOAL DATE ON-TRACK FOR SEPTEMBER 28, 2019.AMARIN CORPORATION PLC - TO DATE, FDA HAS NOT INFORMED AMARIN AS TO WHETHER IT PLANS TO CONVENE AN ADVISORY COMMITTEE MEETING (ADCOM) TO REVIEW SNDA.AMARIN CORPORATION PLC - AMARIN ENDED JUNE 2019 WITH CASH AND CASH EQUIVALENTS OF APPROXIMATELY $221 MILLION.  Full Article

Amarin Reports Q1 Adjusted Non-GAAP Loss Per Share $0.05
Wednesday, 1 May 2019 

May 1 (Reuters) - Amarin Corporation PLC ::REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS.Q1 ADJUSTED NON-GAAP LOSS PER SHARE $0.05 EXCLUDING ITEMS.Q1 REVENUE $73.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $67.3 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.11 -- REFINITIV IBES DATA.Q1 GAAP LOSS PER SHARE $0.07.  Full Article

Amarin Submits Supplemental New Drug Application To U.S. FDA
Thursday, 28 Mar 2019 

March 28 (Reuters) - Amarin Corporation PLC ::AMARIN SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) TO U.S. FDA SEEKING NEW INDICATION FOR VASCEPA (ICOSAPENT ETHYL) TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS BASED ON LANDMARK REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY.OPERATING UNDER ASSUMPTION THAT SNDA WILL BE REVIEWED ON A STANDARD REVIEW CLOCK OF TEN MONTHS RESULTING IN A PDUFA DATE NEAR END OF JAN 2020.  Full Article

American Diabetes Association Issues Critical Update To Standards Of Medical Care In Diabetes
Wednesday, 27 Mar 2019 

March 27 (Reuters) - American Diabetes Association::AMERICAN DIABETES ASSOCIATION ISSUES CRITICAL UPDATE TO STANDARDS OF MEDICAL CARE IN DIABETES.UPDATED SECTION 10 OF LIVING STANDARDS OF CARE TO INCLIDE RECOMMENDATION THAT ICOSAPENT ETHYL BE CONSIDERED FOR PATIENTS WITH ASCVD.  Full Article

Amarin Reports Q4 Adj Non-GAAP Loss Per Share Of $0.09
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - Amarin Corporation PLC ::AMARIN REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS.Q4 ADJUSTED NON-GAAP LOSS PER SHARE $0.09 EXCLUDING ITEMS.Q4 EARNINGS PER SHARE ESTIMATE $-0.07 -- REFINITIV IBES DATA.Q4 GAAP LOSS PER SHARE $0.11.REAFFIRMS THAT EARLIER GUIDANCE HAS NOT CHANGED.SAYS NET PRODUCT REVENUE FOR THREE MONTHS ENDED DECEMBER 31, 2018 AND 2017 WAS $77.1 MILLION AND $53.5 MILLION, RESPECTIVELY.  Full Article

Amarin Reports Q3 Loss Per Share Of $0.08
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Amarin Corporation PLC ::AMARIN REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS.Q3 ADJUSTED NON-GAAP LOSS PER SHARE $0.06 EXCLUDING ITEMS.Q3 EARNINGS PER SHARE VIEW $-0.10 -- THOMSON REUTERS I/B/E/S.Q3 GAAP LOSS PER SHARE $0.08.QTRLY NET PRODUCT REVENUE FOR THREE MONTHS ENDED SEPTEMBER 30, 2018 AND 2017 WAS $55.0 MILLION AND $47.1 MILLION, RESPECTIVELY.PLANS TO SUBMIT SUPPLEMENTAL NDA IN EARLY 2019 SEEKING AN EXPANDED INDICATION FOR VASCEPA IN UNITED STATES.  Full Article

Amarin Reports Q2 GAAP Loss Of $0.12 Per Share
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Amarin Corporation PLC ::AMARIN REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS.Q2 ADJUSTED NON-GAAP LOSS PER SHARE $0.10 EXCLUDING ITEMS.Q2 EARNINGS PER SHARE VIEW $-0.09 -- THOMSON REUTERS I/B/E/S.Q2 GAAP LOSS PER SHARE $0.12.QTRLY NET PRODUCT REVENUE $52.5 MILLION VERSUS $44.9 MILLION.  Full Article

Amarin Says Settlement Agreement Provides That Co Will Pay Teva $2 Mln
Thursday, 24 May 2018 

May 24 (Reuters) - Amarin Corporation PLC ::AMARIN CORPORATION SAYS SETTLEMENT AGREEMENT WITH TEVA PROVIDES THAT CO WILL PAY TEVA $2 MILLION - SEC FILING.AMARIN CORPORATION PLC - OTHER TERMS OF SETTLEMENT AGREEMENT WITH TEVA ARE CONFIDENTIAL.  Full Article

Amarin's Vascepa cuts occurrence of serious heart problems 30 pct -study

March 18 A high dose of Amarin Corp's Omega-3 drug Vascepa significantly reduced the occurrence of first and subsequent heart attacks, strokes and other serious heart problems in high-risk patients already taking cholesterol medication by even more than initially reported, according to data presented on Monday.